IIT study links collagen to type 2 diabetes progression, raising supplement safety questions

A team at India's Institute of Technology Bombay has uncovered something unexpected in the biology of type 2 diabetes: collagen, the body's most abundant protein, appears to be making the disease worse, not better. The finding, published in the Journal of the American Chemical Society, centers on a hidden interaction between collagen and amylin, a hormone that works alongside insulin in the pancreas. For the roughly 500 million people worldwide living with type 2 diabetes, the discovery raises an uncomfortable question about a supplement many of them take without hesitation.

Collagen is everywhere in the human body—it gives skin its firmness, bones their strength, cartilage its resilience. As people age, the body makes less of it, which is why wrinkles deepen and joints stiffen. The supplement industry has capitalized on this biological reality, marketing collagen powders, capsules, and drinks as a way to restore what time takes away. For people managing diabetes, collagen supplements seem like an especially safe choice: they're low in calories, contain no carbohydrates, and promise benefits for skin elasticity and joint health. Millions consume them regularly, often without a second thought.

The IIT Bombay research, conducted in collaboration with IIT Kanpur and the Chittaranjan National Cancer Institute in Kolkata, reveals why caution may be warranted. In type 2 diabetes, amylin—the hormone produced alongside insulin—can clump together in ways that damage the very cells responsible for making insulin. This makes blood sugar harder to control and the disease harder to manage. What the researchers discovered is that collagen I, the structural form of collagen found in skin, bones, and connective tissue, acts like a scaffold that accelerates this toxic clumping process. The amylin doesn't just aggregate randomly; it coats the collagen fibers like a train following tracks, forming stable clusters that cells struggle to clear away. The result is more damage to the pancreas and faster disease progression.

When the team tested their theory on diabetic mice and human tissue samples, the pattern held. As diabetes advanced, both collagen and amylin levels rose, compounding the damage to insulin-producing cells. "It almost seems that the amylin completely physically coats the collagen surface, forming stable aggregates that are more difficult for cells to clear," said Shamik Sen, the bioscientist who led the project at IIT Bombay. "Rather than aggregating in isolation, amylin appears to use the collagen fibres like train tracks, accelerating its accumulation and increasing toxicity to nearby cells." The implication is stark: many existing diabetes treatments, which focus on processes inside cells, may be missing a crucial piece of the puzzle. If the link between amylin and collagen isn't broken, Sen noted, the toxic conditions in the pancreas cannot be fully resolved.

The study does not directly test whether collagen supplements worsen diabetes. When people ingest collagen, their digestive system breaks it down into short amino acid chains that enter the bloodstream—a different form than the intact collagen I studied in the research. Still, the findings are unsettling enough to warrant investigation. Some earlier research has suggested that collagen supplements might actually help diabetics by stabilizing blood sugar or improving how their bodies use insulin. But the IIT Bombay work suggests a potential downside that previous studies may have overlooked. For now, the researchers are using advanced cryo-electron microscopy to build detailed three-dimensional models of how amylin and collagen interact at the molecular level. If they can map this interaction precisely, they may be able to design drugs that disrupt it—potentially opening a new avenue for treating a disease that affects one in ten adults globally and shows no signs of slowing down.